Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 8Phase 1 7Phase NA 3Phase 2/3 3Phase 3 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Oropharyngeal Neoplasms 3Myelodysplastic Syndromes 3Leukemia 3Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma of Lung 2Warts 1Vasculitis 1Urinary Bladder Neoplasms 1Spinal Cord Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1

Interventions

Specimen Handling 2Radiotherapy, Intensity-Modulated 2Platinum 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cisplatin 2Cetuximab 21,2-diaminocyclohexaneplatinum II citrate 2(225)Ac-DOTA-c(RGDyK) 2durvalumab 1atezolizumab 1Radiotherapy, Image-Guided 1Nivolumab 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Oropharyngeal Neoplasms × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03952585 2026-06-01

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
384 enrolled 22 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡